SCHEMBL6832285

SCHEMBL6832285

CCOC(=O)/C=C/c1ccc(N=O)c(C[C@H](NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.42
DPP4 P27487 1/20 0.42
MAOB P27338 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
TACR1 P25103 1/20 0.40
SCN9A Q15858 1/20 0.39
CYP3A4 P08684 1/20 0.39
FDPS P14324 1/20 0.39
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
HDAC3 O15379 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6832287 0.85 TACR1 (0.39) TACR1SCN9APPARGPPARANPC1
SCHEMBL3775140 0.83 GSTP1 (0.42) TTRDPP4MAOBCA12CA1
SCHEMBL3775142 0.83 GSTP1 (0.42) TTRDPP4MAOBCA12CA1
SCHEMBL6832286 0.79 AAK1 (0.45) TACR1NPC1RAB9AALDH1A1MAPT
SCHEMBL3771587 0.77 AKR1B1 (0.43) TTRDPP4MAOBCA12CA1
SCHEMBL3771590 0.77 AKR1B1 (0.43) TTRDPP4MAOBCA12CA1
SCHEMBL10249595 0.74 TACR1 (0.45) TACR1SCN9ACYP3A4
SCHEMBL14051411 0.73 ITGB3 (0.46) CA12CA1CA2CA7CA9
SCHEMBL5108573 0.72 CTSL (0.52) CA12CA7CA9CA14TACR1
SCHEMBL5108576 0.72 CTSL (0.52) CA12CA7CA9CA14TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183238-B2 Bicyclic and tricyclic compounds as KAT II inhibitors PFIZER INC. (US) 2012-05-22 US disclosed
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors PFIZER INC 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors KAT2A, KAT2B, KAT6B TTR 2200/4885DPP4 4353/4885MAOB 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.